Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)

Joseph Carmicheal, Asish Patel, Vipin Dalal, Pranita Atri, Amaninder S. Dhaliwal, Uwe A. Wittel, Mokenge P. Malafa, Geoffrey Talmon, Benjamin J. Swanson, Shailender Singh, Maneesh Jain, Sukhwinder Kaur, Surinder K. Batra

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.

Original languageEnglish (US)
Article number188318
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number1
StatePublished - Jan 2020


  • Biomarker
  • Early detection
  • IPMN
  • Pancreatic cancer
  • Pancreatic cystic lesions
  • Pancreatic ductal adenocarcinoma
  • Radiomics

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)'. Together they form a unique fingerprint.

Cite this